Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-25
2007-12-25
Qian, Celine (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024100
Reexamination Certificate
active
10781055
ABSTRACT:
The present invention relates to chemically synthesized promoters that circumvent the disadvantages of the universal CMV promoter/enhancer elements. The promoter may be used in a variety of applications, particularly in genetic immunization. The chemically synthesized promoter overcomes the common problems of the CMV promoter element such as: low transgene expression levels, transient expression, and the large amount of plasmid DNA needed for intramuscular injection in subjects.
REFERENCES:
patent: 4683202 (1987-07-01), Mullis
patent: 5717058 (1998-02-01), Matthews et al.
patent: 5928906 (1999-07-01), Köster et al.
patent: 6410210 (2002-06-01), Gabriel
patent: 6410241 (2002-06-01), Sykes et al.
patent: 6461606 (2002-10-01), Flotte et al.
patent: 6525189 (2003-02-01), Kim
patent: 6900018 (2005-05-01), Sykes et al.
patent: 7018833 (2006-03-01), Sykes et al.
patent: 7018836 (2006-03-01), Price
patent: 2002/0055173 (2002-05-01), Parks et al.
patent: 2002/0146733 (2002-10-01), Sykes et al.
patent: 2002/0150940 (2002-10-01), Sykes et al.
patent: 2002/0155508 (2002-10-01), Sykes et al.
patent: 2002/0160402 (2002-10-01), Sykes et al.
patent: 2003/0104356 (2003-06-01), Berger
patent: 2003/0129169 (2003-07-01), Krohn et al.
patent: 2003/0186424 (2003-10-01), Roninson et al.
Morral N, O'Neal W, Zhou H, Langston C, Beaudet A. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther. Jul. 1;8(10):1275-86.
Hoag H, Gore J, Barry D, Mueller C. 1999.Gene therapy expression vectors based on the clotting Factor IX promoter. Gene Ther. Sep.;6(9):1584-9.
K Struhl-. 1995. Yeast Transcriptional Regulatory Mechanisms Annu Rev Genet. 5vol. 29: 651-674.
Wahren B, Ljungberg K, Rollman E, Levi M, Zuber B, Kjerrstrom Zuber A, Hinkula J, Leandersson AC, Calarota S, Hejdeman B, Bratt G, Sandstrom E. 2002. HIV subtypes and recombination strains-strategies for induction of immune responses in man.Vaccine. May 6;20(15):1988-93.
Barry et al., “Protection against mycoplasma infection using expression-library immunization,”Nature, 377(6550):632-635, 1995.
Breathnack and Chambon, “Organization and expression of eucaryotic split genes coding for proteins,”Annu. Rev. Biochem., 50:349-383, 1981.
Burke et al., “The DPE, a conserved downstream core promoter element that is functionally analogous to the TATA box,”Cold Harbor Symposia on Quantitative Biology, vol. LXIII, 75-82, The Mechanisms of Transcription, 1998.
Faisst and Meyer, “Compilation of vertebrate-encoded transcription factors,”Nucleic Acids Research, 20(1):3-26, 1992.
Fujita et al., “Delimitation and properties of DNA sequences required for the regulated expression of human interferon-β gene,”Cell, 41(2):489-496, 1985.
Fynan et al., “DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations,”Proc. Natl. Acad. Sci., USA, 90:11478-11482, 1995.
Graves et al., “Homologous recognition of a promoter domain common to the MSV LTR and the HSV tk gene,”Cell, 44(4):565-576, 1986.
Gronostajski, “Site-specific DNA binding of nuclear factor I: effect of the spacer region,”Nucleic Acids Research, 15(14):5545-5559, 1987.
Harms and Splitter, “Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expresion driven by the mammalian MHC I promoter,”Hum. Gene. Ther., 6(10):1291-1297, 1995.
Hu et al., “Transcriptional factor AP-4 contains multiple dimerization domains that regulate dimer specificity,”Genes Dev., 4(10):1741-1752, 1990.
Kadonaga et al., “Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain,”Cell, 51(6):1079-1090, 1987.
Liu and Green, “A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein,”Cell, 61(7):1217-1224, 1990.
McDonnel and Askari., “Molecular medicine,”New Engl. J. Med., 334(1):42-45, 1996.
Mitchell and Tijian, “Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins,”Science, 245(4916):371-378, 1989.
Pardoll et al., “Exposing the immunology of naked DNA vaccines,”Immunity, 3:165-169, 1995.
Perlmann et al., “Determination for selective RAR and TR recognition of direct repeat HREs,”Genes Dev., 7B:1411-1422, 1993.
Pollock et al., “Human SRF-related proteins: DNA-binding properties and potential regulatory targets,”Genes Dev., 5(12A):2327-2341, 1991.
Qin et al., “Promoter attenuation in gene therapy: interferon-γ and tumor necrosis factor-α inhibit transgene expression,”Hum. Gene Ther., 8(17):2019-2029, 1997.
Ritter et al., “Stimulatory and inhibitory action of cytokines on the regulation of hCMV-IE promoter activity in human endothelial cells,”Cytokine, 12(8):1163-1170, 2000.
Robinson, “DNA based vaccines: new possibilities for disease prevention and treatment,”Can. Med. Assoc. J., 152(10):1629-1632, 1995.
Ruvkun and Finney, “Regulation of transcriptional and cell identity by POU domain proteins,”Cell, 64(3):475-478, 1991.
Smale and Baltimore, “The ‘initiator’ as a transcription control element,”Cell, 57(1):103-113, 1989.
Spooner et al., “DNA vaccination for cancer treatment,”Gene Therapy, 2:173-180, 1995.
Tanaka et al., “Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system,”Mol. Cell. Biol., 13(8):4531-4538, 1993.
Virbasius, “NRF-1, an activator involved in nuclear-mitochondrial interactions, utilizes a new DNA-binding domain conserved in a family of developmental regulators,”Genes Dev., 7(12A):2431-2445, 1992.
Williams and Tijian, “Analysis of the DNA-binding and activation properties of the human transcription factor AP-2,”Genes Dev., 5(4):670-682, 1991.
Yen et al., “An alternative spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins,”Proc. Natl. Acad. Sci., USA, 88(12):5077-5081, 1991.
Johnston Stephen
Qu Bao-Xi
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Mitchell Laura M
Qian Celine
LandOfFree
Rationally designed and chemically synthesized promoter for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rationally designed and chemically synthesized promoter for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rationally designed and chemically synthesized promoter for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3865203